Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

Annals of Hematology

Volumn 89, Issue 8, 2010, Pages 803-811

  Palumbo, A ^a   Davies, F ^b   Kropff, M ^c   Blade J ^d   Delforge, M ^e   Leal Da Costa, F ^f   Garcia Sanz, R ^g   Schey, S ^h   Facon, T ⁱ   Morgan, G ^b   Moreau, P ^j  

^a UNIVERSITY OF TURIN   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h KING S COLLEGE HOSPITAL   (United Kingdom)

ⁱ LILLE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITÉ DE NANTES   (France)

more..

Author keywords

MM; Myeloma; Thalidomide; Treatment guidelines

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; SILDENAFIL; THALIDOMIDE; THYROTROPIN;

ANEMIA; ARTICLE; ARTIFICIAL HEART PACEMAKER; BEDTIME DOSAGE; BLEEDING; BRADYCARDIA; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONSTIPATION; COORDINATION DISORDER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; DYSESTHESIA; EDEMA; EPIDERMOLYSIS; FATIGUE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; IMPOTENCE; INFECTION; KIDNEY CLEARANCE; KIDNEY FAILURE; MEASLES LIKE RASH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PREGNANCY OUTCOME; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; RECURRENCE RISK; RISK FACTOR; SKIN TINGLING; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THYROID DISEASE; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WEAKNESS; AGED; CONFERENCE PAPER; CONSENSUS; EUROPE; PRACTICE GUIDELINE; SURVIVAL RATE;

AGED; CONSENSUS; EUROPE; GUIDELINES AS TOPIC; HUMANS; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; RISK FACTORS; SURVIVAL RATE; THALIDOMIDE; THROMBOEMBOLISM;

EID: 77954681998     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0925-1     Document Type: Article

References (75)

1. Smith A, Wisloff F, Samson D (2005) Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 132:410-451
2. Anderson KC. NCCN Clinical Practice Guidelines 2008
3. Myeloma Trialists' Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832-3842
4. Singhal S, Meta J, Disakan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571
5. Barlogie B, Disikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492-494
6. van Rhee F, Dhodapkar M, Shaughnessy JD Jr et al (2008) First thalidomide clinical trial in multiple myeloma: A decade later. Blood 112:1035-1038
7. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831
8. Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218
9. Hulin C, Virion J, Leleu X et al (2009) Efficacy of melphalanprednisone- thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. J Clin Oncol 27: 3664-3670
10. Waage A, Gimsing P, Juliusson G et al (2007) Melphalanprednisone- thalidomide to newly diagnosed patients with multiple myeloma: A placebo controlled randomised phase 3 trial. ASH Annual Meeting abstracts Blood 110:78
11. Wijermans P (2009) Melphalan + prednisone versus melphalan + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: Final analysis of the Dutch Cooperative Group HOVON 49 study. Blood 112. Abstract 649
12. Palumbo A, Bringhen S, Liberati AM et al (2008) Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 112:3107-3114
13. Dispenzieri A, Rajkumar SV, Gertz MA et al (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): Consensus statement. Mayo Clin Proc 82:323-341
14. Thalidomide Celgene SmPC (2008)
15. Palumbo A, Falco P, Corradini P et al (2007) Melphalan, prednisone and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian multiple myeloma network. J Clin Oncol 25:4459-4465
16. Palumbo A, Rajkumar SV, Dimopoulos MA et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423
17. Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 158:585-593
18. Heit JA, Silverstein MD, Mohr DN (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: A populationbased, cohort study. Arch Intern Med 159:445-453
19. Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: Determination of frequency and characteristics. Thromb Haemost 87:575-579
20. Blom JW, Doggen CJ, Osanto S et al (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722 (Pubitemid 40216041)
21. Boersma RS, Jie KS, Verbon A et al (2008) Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 19:433-1432
22. El Accaoui RN, Shamseddeen WA, Taher AT (2007) Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 97:1031-1036
23. Zangari M, Siegel E, Barlogie B et al (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 100:1168-1171
24. Zangari M, Barlogie B, Thertulien R et al (2003) Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival. Clin Lymphoma 4:32-35
25. Schutt P, Ebeling P, Buttkereit U et al (2005) Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 74:40-46
26. Johnson DC, Corthals S, Ramos C et al (2008) Genetic associations with thalidomide mediated venous thrombotic events in myeloma using targeted genotyping. Blood 112:4924-4934
27. Palumbo A, Cavo M, Bringhen S et al (2007) A prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. Blood 110. Abstract 310
28. Costa G, Engle RL Jr, Schilling A et al (1973) Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. Am J Med 54:589-599
29. Plasmati R, Pastorelli F, Cavo M et al (2007) Neuropathy in multiple myeloma treated with thalidomide: A prospective study. Neurology 69:573-581
30. San Miguel J, Blade J, Boccadoro M et al (2006) A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11:51-61 (Pubitemid 43152686)
31. Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120
32. Ghobrial IM, Rajkumar SV (2003) Management of thalidomide toxicity. J Support Oncol 1:194-205
33. Cavaletti G, Beronio A, Reni L et al (2004) Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study. Neurology 62:2291-2293
34. Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507-4514
35. Kaur A, Yu SS, Lee AJ (2003) Thalidomide-induced sinus bradycardia. Ann Pharmacother 37:1040-1043
36. Fahdi IE, Gaddam V, Saucedo JF et al (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93:1052-1055
37. Bladé J, Esteve J, Rosiñol L et al (2001) Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 28:588-592
38. García-Sanz R, González-Porras JR, Hernández JM et al (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18:856-863
39. Mateos MV, Oriol A, Martínez J et al (2008) Bortezomib (Velcade)- melphalan-prednisone (VMP) versus velcade-thalidomideprednisone (VTP) in elderly untreated multiple myeloma patients: Which is the best partner for velcade: An alkylating or an immunomodulator agent? Blood 112. Abstract 651
40. Hall VC, El-Azhary RA, Bouwhuis S et al (2003) Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 48:548-552
41. Horowitz SB, Stirling AL (1999) Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy 19:1177-1180
42. Rajkumar SV, Gertz MA, Witzig TE (2000) Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 343:972-973
43. Nijsten T, Meuleman L, Schroyens W et al (2002) Thalidomideinduced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone. Dermatology 204:365-367
44. Amin N, Brancaccio R, Cohen D (2006) Cutaneous reactions to injectable corticosteroids. Dermatitis 17:143-146
45. Dimopoulos MA, Kastritis E, Rosinol L et al (2008) Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493
46. Eriksson T, Höglund P, Turesson I et al (2003) Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. J Pharm Pharmacol 55:1701-1706
47. Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475
48. Pineda-Roma M, Tricot G (2007) High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol 153:182-194
49. Palumbo A, Boccadoro M (2007) A new standard of care for elderly patients with myeloma. Lancet 370:1191-1192 (Pubitemid 47503289)
50. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 359:906-917
51. Wang M, Dimopoulos M, Chen C et al (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445-4451
52. Sonneveld P, Hajek R, Nagler A et al (2008) Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112:1529-1537
53. Sidra G, Williams CD, Russell NH et al (2006) Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 91:862-863
54. Fonseca R, Stewart AK (2007) Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Mol Cancer Ther 6:802-810
55. Barlogie B, Pineda-Roman M, van Rhee F et al (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121
56. Dimopoulos MA, Eleutherakis-Papaiakovou V (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 117:508-515
57. Murphy PT, O'Donnell JR (2006) Thalidomide induced impotence in male hematology patients: A common but ignored complication? Haematologica 92:1440
58. Rajkumar SV, Gertz MA, Lacy MQ et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17:775-779
59. Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19
60. Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436
61. Cavo M, Zamagni E, Tosi P et al (2004) First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89:826-831
62. Rajkumar SV, Hayman S, Gertz M et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319-4323
63. Osman K, Comenzo R, Rajkumar SV (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951-1952
64. Zervas K, Dimopoulos MA, Hatzicharissi E et al (2004) Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncol 15:134-138
65. Wu P, Davies FE, Horton C et al (2006) The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin- methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: A case-matched analysis. Leuk Lymphoma 47:2335-2338
66. Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030
67. Neben K, Moehler T, Benner A et al (2002) Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377-3382
68. Schey SA, Cavenagh J, Johnson R et al (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 27:909-914
69. Anagnostopoulos A, Weber D, Rankin K et al (2003) Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 121:768-771 (Pubitemid 36718193)
70. Palumbo A, Bertola A, Falco P et al (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318-324
71. Baz R, Li L, Kottke-Marchant K et al (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80:1568-1574
72. Dimopoulos MA, Hamilos G, Zomas A et al (2004) Pulsed cyclophosphamide, thalidomide and dexamethasone: An oral regimen for previously treated patients with multiple myeloma. Hematol J 5:112-117
73. Kropff MH, Lang N, Bisping G et al (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122:607-616
74. Suvannasankha A, Fausel C, Juliar BE et al (2007) Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist 12:99-106
75. Lee CK, Barlogie B, Munshi N et al (2003) DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732-2739